on Biotest AG (isin : DE0005227201)
Dr. Jörg Schüttrumpf Resigns from Biotest AG Management Board
Biotest AG has announced that Dr. Jörg Schüttrumpf will step down from his position as Chief Scientific Officer and member of the Management Board effective August 31, 2024. He will focus on his role as Chief Scientific Innovation Officer for the Grifols Group.
During his tenure, Dr. Schüttrumpf led the development of key products such as Fibrinogen, Trimodulin, and Yimmugo®, all integral to Biotest's Next Level expansion program and the Grifols Group pipeline.
Responsibilities formerly held by Dr. Schüttrumpf will now be managed by Mr. Janssen, CEO of Biotest AG. The company expressed its gratitude for his contributions and looks forward to continued collaboration within the Grifols Group.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Biotest AG news